X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs ABBOTT INDIA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD ABBOTT INDIA MERCK LTD/
ABBOTT INDIA
 
P/E (TTM) x 50.3 38.5 130.5% View Chart
P/BV x 7.6 9.9 76.6% View Chart
Dividend Yield % 0.4 0.7 53.5%  

Financials

 MERCK LTD   ABBOTT INDIA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
ABBOTT INDIA
Mar-18
MERCK LTD/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,0606,110 17.3%   
Low Rs6233,996 15.6%   
Sales per share (Unadj.) Rs632.41,552.2 40.7%  
Earnings per share (Unadj.) Rs45.7188.8 24.2%  
Cash flow per share (Unadj.) Rs62.3196.4 31.7%  
Dividends per share (Unadj.) Rs11.0055.00 20.0%  
Dividend yield (eoy) %1.31.1 120.1%  
Book value per share (Unadj.) Rs388.8796.6 48.8%  
Shares outstanding (eoy) m16.6021.25 78.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.3 40.9%   
Avg P/E ratio x18.426.8 68.8%  
P/CF ratio (eoy) x13.525.7 52.5%  
Price / Book Value ratio x2.26.3 34.1%  
Dividend payout %24.129.1 82.6%   
Avg Mkt Cap Rs m13,969107,376 13.0%   
No. of employees `0001.63.3 47.7%   
Total wages/salary Rs m1,4873,937 37.8%   
Avg. sales/employee Rs Th6,631.99,929.3 66.8%   
Avg. wages/employee Rs Th939.21,185.1 79.2%   
Avg. net profit/employee Rs Th479.41,207.7 39.7%   
INCOME DATA
Net Sales Rs m10,49832,985 31.8%  
Other income Rs m2421,170 20.7%   
Total revenues Rs m10,74134,155 31.4%   
Gross profit Rs m1,1355,245 21.6%  
Depreciation Rs m276162 170.2%   
Interest Rs m038 0.0%   
Profit before tax Rs m1,1026,215 17.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3432,203 15.6%   
Profit after tax Rs m7594,012 18.9%  
Gross profit margin %10.815.9 68.0%  
Effective tax rate %31.135.4 87.9%   
Net profit margin %7.212.2 59.4%  
BALANCE SHEET DATA
Current assets Rs m6,41022,655 28.3%   
Current liabilities Rs m8,8286,681 132.1%   
Net working cap to sales %-23.048.4 -47.6%  
Current ratio x0.73.4 21.4%  
Inventory Days Days5865 89.0%  
Debtors Days Days3829 131.7%  
Net fixed assets Rs m1,406835 168.3%   
Share capital Rs m166213 78.1%   
"Free" reserves Rs m6,28616,715 37.6%   
Net worth Rs m6,45516,928 38.1%   
Long term debt Rs m00-   
Total assets Rs m8,82824,162 36.5%  
Interest coverage xNM163.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.4 87.1%   
Return on assets %8.616.8 51.3%  
Return on equity %11.823.7 49.6%  
Return on capital %17.136.9 46.2%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m959369 260.2%   
Fx outflow Rs m2,6123,807 68.6%   
Net fx Rs m-1,653-3,438 48.1%   
CASH FLOW
From Operations Rs m1,0701,527 70.1%  
From Investments Rs m-750-2,148 34.9%  
From Financial Activity Rs m-150-1,024 14.6%  
Net Cashflow Rs m171-1,646 -10.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 7.9 230.4%  
FIIs % 1.0 0.1 1,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.1 170.2%  
Shareholders   28,591 18,270 156.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty Hits Fresh Record High; Sensex Up Over 330 Points(12:30 pm)

After opening the day on a positive note, stock markets in India continued their momentum and went on to scale their record-high levels.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA at All Time High; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Aug 20, 2018 | Updated on Aug 20, 2018

TORRENT PHARMA share price has hit an all time high at Rs 1,790 (up 0.2%). The BSE HEALTHCARE Index is up by 0.9%. Among the top gainers in the BSE HEALTHCARE Index today are TORRENT PHARMA (up 0.2%) and GSK PHARMA (up 1.6%). The top losers include SANOFI INDIA (down 0.2%) and ABBOTT INDIA (down 0.3%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Aug 20, 2018 02:07 PM

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - SUVEN LIFE COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS